|
|
|
|
| LEADER |
04939nam a22005295i 4500 |
| 001 |
978-3-319-46038-3 |
| 003 |
DE-He213 |
| 005 |
20210618054224.0 |
| 007 |
cr nn 008mamaa |
| 008 |
161226s2017 gw | s |||| 0|eng d |
| 020 |
|
|
|a 9783319460383
|9 978-3-319-46038-3
|
| 024 |
7 |
|
|a 10.1007/978-3-319-46038-3
|2 doi
|
| 050 |
|
4 |
|a RC648-665.2
|
| 072 |
|
7 |
|a MJG
|2 bicssc
|
| 072 |
|
7 |
|a MED027000
|2 bisacsh
|
| 072 |
|
7 |
|a MJG
|2 thema
|
| 082 |
0 |
4 |
|a 616.4
|2 23
|
| 245 |
1 |
0 |
|a Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors
|h [electronic resource] /
|c edited by Karel Pacak, David Taïeb.
|
| 250 |
|
|
|a 1st ed. 2017.
|
| 264 |
|
1 |
|a Cham :
|b Springer International Publishing :
|b Imprint: Humana,
|c 2017.
|
| 300 |
|
|
|a XIV, 484 p. 104 illus., 79 illus. in color.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 490 |
1 |
|
|a Contemporary Endocrinology,
|x 2523-3785
|
| 505 |
0 |
|
|a Classification of neuroendocrine tumors -- Molecular genetics of Pheochromocytoma and paraganglioma -- Molecular Genetics of MEN1-related Neuroendocrine Tumors -- Molecular genetics of MEN2-related neuroendocrine tumors -- Molecular genetics of Neuroblastoma -- Molecular Genetics of Gastroenteropancreatic Neuroendocrine Tumors -- Current and future radiopharmaceuticals in neuroendocrine tumors imaging -- SPECT/CT, PET/CT and PET/MR: Principles -- Internal dosimetry: Principles and Applications to NET -- Principles and Application of Molecular Imaging for Personalised Medicine and Guiding Interventions in Neuroendocrine Tumors -- Tumor metabolism and metabolomics of pheochromocytomas and paragangliomas -- Radionuclide imaging of pheochromocytoma and paraganglioma in the era of multi-omics -- Radionuclide imaging of Head and neck PGLs -- Radionuclide imaging of Chromaffin cell tumors -- Radionuclide imaging of Gastrointestinal neuroendocrine tumors -- Radionuclide imaging of Pancreatic neuroendocrine tumors -- Radionuclide imaging of Pulmonary, thymic neuroendocrine tumors and other neuroendocrine tumors -- Radionuclide imaging of Medullary thyroid carcinoma -- 131I-MIBG therapy for pheochromocytoma/paraganglioma and neuroblastoma -- Somatostatin receptors-based radionuclide therapy -- Alpha radionuclide therapy: Principles and Applications to NET -- Nanoparticles for Radionuclide Imaging and Therapy: Principles.
|
| 520 |
|
|
|a Based on the most novel approaches and cutting-edge clinical and scientific information regarding radionuclide imaging and therapies for neuroendocrine tumors, this clinical guidebook represents a unique collaborative effort between endocrinologists, nuclear physicians, oncologists, surgeons, physicists, radio-pharmacists and geneticists. It begins with the embryology, classification and molecular genetics of gastroenteropancreatic neuroendocrine tumors and carcinoids, chromaffin cell tumors, and MEN1- and MEN2-related tumors. Following a chapter on radiopharmaceuticals in neuroendocrine imaging, it turns to the physics and technology of current and cutting-edge radiology, including SPECT/CT and PET/CT and PET/MR. Discussing of radionuclide imaging covers the tumors mentioned above, as well as pulmonary and thymic neuroendocrine tumors and medullary thyroid carcinoma. A presentation of radionuclide therapies follows, including 131I-MIBG therapy, somatostatin receptor-based therapy, and alpha radionuclide therapy, as well as the role of nanoparticles. Comprehensive and up-to-date, Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors will assist and guide physicians who encounter patients with these conditions, either from a diagnostic or therapeutic standpoint, and particularly emphasizes the current and emerging medical devices and imaging and therapeutic options.
|
| 650 |
|
0 |
|a Endocrinology .
|
| 650 |
|
0 |
|a Nuclear medicine.
|
| 650 |
|
0 |
|a Oncology .
|
| 650 |
1 |
4 |
|a Endocrinology.
|0 https://scigraph.springernature.com/ontologies/product-market-codes/H33053
|
| 650 |
2 |
4 |
|a Nuclear Medicine.
|0 https://scigraph.springernature.com/ontologies/product-market-codes/H29048
|
| 650 |
2 |
4 |
|a Oncology.
|0 https://scigraph.springernature.com/ontologies/product-market-codes/H33160
|
| 700 |
1 |
|
|a Pacak, Karel.
|e editor.
|4 edt
|4 http://id.loc.gov/vocabulary/relators/edt
|
| 700 |
1 |
|
|a Taïeb, David.
|e editor.
|4 edt
|4 http://id.loc.gov/vocabulary/relators/edt
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer Nature eBook
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783319460369
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783319460376
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783319834269
|
| 830 |
|
0 |
|a Contemporary Endocrinology,
|x 2523-3785
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-319-46038-3
|
| 912 |
|
|
|a ZDB-2-SME
|
| 912 |
|
|
|a ZDB-2-SXM
|
| 950 |
|
|
|a Medicine (SpringerNature-11650)
|
| 950 |
|
|
|a Medicine (R0) (SpringerNature-43714)
|
